Clinical, kinematic and electrophysiological characterisation of patients with multiple systems atrophy and pharmacological modulation by venlafaxin.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034001

Enrollment

Registered

2024-04-22

Start date

2024-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G23.2

Interventions

Group 1: Patients with possible or probable multiple systems atrophy according to criteria of the Movement Disorders Society - Administration of the serotonin-norepinephrine reuptake inhibitor venlaf

Eligibility

Sex/Gender

All

Age

30 Years to No maximum

Inclusion criteria

Inclusion criteria: - age > 30 years - sporadic onset and gradual progression - clinical diagnosis of probable or possible MSA-P according to MDS-criteria

Exclusion criteria

Exclusion criteria: - severe impairment of vision - no ability to give informed consent

Design outcomes

Secondary

Measure	Time frame
Changes in parameters of gait analysis, pupillometry and EEG as well as changes in clinical scores in the Unified MSA Rating Scale (UMSARS), the Montreal Cognitive Assessment (MoCA-Test), the Three-clap Test, Luria-sequence, verbal fluency, Frontal Assessment Battery (FAB), Schwab and England Activities of Daily Living (SEADL), MSA-Qualtity of Life Scale (MSA-QoL) and Munich Dysphagia Test (MDT). All parameters are assessed before and after Venlafaxin intervention.	—

Measure

Time frame

Changes in parameters of gait analysis, pupillometry and EEG as well as changes in clinical scores in the Unified MSA Rating Scale (UMSARS), the Montreal Cognitive Assessment (MoCA-Test), the Three-clap Test, Luria-sequence, verbal fluency, Frontal Assessment Battery (FAB), Schwab and England Activities of Daily Living (SEADL), MSA-Qualtity of Life Scale (MSA-QoL) and Munich Dysphagia Test (MDT). All parameters are assessed before and after Venlafaxin intervention.

—

Primary

Measure	Time frame
Change in neuropsychiatric/cognitive symptoms assessed by Trail Making Test (TMT), Starkstein Apathy Scale (SAS), and Geratric Depression Scale (GDS) after treatment with Venlafaxin for at least 4 weeks compared to scores before treatment.	—

Countries

Germany

Contacts

Public ContactMonika Pötter-Nerger

Universitätsklinikum Hamburg-Eppendorf

m.poetter-nerger@uke.de040 7410 0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026